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Objectives The aim of this study was to evaluate whether coronary heart disease (CHD)-susceptibility loci identified by
genome-wide association studies of the general population also contribute to CHD in type 2 diabetes.
Background No study has examined the effects of these genetic variants on CHD in diabetic patients.
Methods We genotyped 15 genetic markers of 12 loci in 3 studies of diabetic patients: the prospective Nurses’ Health
Study (309 CHD cases, and 544 control subjects) and Health Professional Follow-up Study (345 CHD cases, and
451 control subjects) and the cross-sectional Joslin Heart Study (422 CHD cases, and 435 control subjects).
Results Five single-nucleotide polymorphisms, rs4977574 (CDKN2A/2B), rs12526453 (PHACTR1), rs646776 (CELSR2-
PSRC1-SORT1), rs2259816 (HNF1A), and rs11206510 (PCSK9) showed directionally consistent associations
with CHD in the 3 studies, with combined odds ratios (ORs) ranging from 1.17 to 1.25 (p  0.03 to 0.0002).
None of the other single-nucleotide polymorphisms reached significance in individual or combined analyses. A
genetic risk score (GRS) was created by combining the risk alleles of the 5 significantly associated loci. The OR
of CHD/GRS unit was 1.19 (95% confidence interval: 1.13 to 1.26; p  0.0001). Individuals with GRS 8
(19% of diabetic subjects) had almost a 2-fold increase in CHD risk (OR: 1.94, 95% confidence interval:
1.60 to 2.35) as compared with individuals with GRS 5 (30% of diabetic subjects). Prediction of CHD was
significantly improved (p  0.001) when the GRS was added to a model including clinical predictors in the
combined samples.
Conclusions Our results illustrate the consistency and differences in the determinants of genetic susceptibility to CHD
in diabetic patients and the general populations. (J Am Coll Cardiol 2011;58:2675–82) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.054Mortality due to coronary heart disease (CHD) has been
declining overall during the past few decades in most
industrialized countries (1). However, during the same
ime period, the number of CHD deaths attributable to
iabetes has been increasing (2). Two factors account for
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Manuscript received July 19, 2011, accepted August 10, 2011.these contrasting trends. First, although the prevalence of
other risk factors—such as smoking, hypertension, and
hypercholesterolemia— has been reduced by prevention
programs, the incidence of diabetes has been steadily
rising (3). Second, the excess cardiovascular risk experi-
enced by diabetic subjects (a 2- to 4-fold increase as
compared with the nondiabetic population) has not
significantly declined during the same period of time (2).
Clearly, there is an urgent need for more effective
approaches to curb the current diabetes epidemic and to
prevent CHD in those subjects who have developed
diabetes. However, little is known about the factors
underlying the excess cardiovascular risk in diabetic
patients.
Studies in diabetic and nondiabetic subjects suggest that
the risk of CHD is influenced by genetic factors (4), and a
number of predisposing loci have been recently identified in
HP
t
n
(
l
D
fi
N
d
d
c
b
s
d
N
s
b
c
b
H
H
i
a
o
2
r
H
t
z
e
w
r
d
e
b
s
a
3
w
a
s
r
s
t
t
a
a
a
r
C
a
a
b
m
e
h
r
i
6
m
c
w
t
M
l
i
2676 Qi et al. JACC Vol. 58, No. 25, 2011
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genome-wide association studies
(GWAS) (5–9). However, whether
these genetic markers predispose
to increased cardiovascular com-
plications in diabetes remain
uncertain.
In this study, we genotyped 12
CHD-susceptibility loci identi-
fied by GWAS of the general
populations and examined their
associations with CHD risk in 3
independent cohorts of patients
with type 2 diabetes. We also
assessed the joint genetic effects
of these loci by creating a genetic
risk score (GRS) and evaluated
its prediction value for CHD
among diabetic patients.
Methods
Study subjects. DIABETIC CO-
ORTS IN NURSES’ HEALTH STUDY AND HEALTH
ROFESSIONAL FOLLOW-UP STUDY. The study samples for
he present analysis were selected from 2 diabetic cohorts
ested in the NHS (Nurses’ Health Study) (10) and HPFS
Health Professional Follow-Up Study) (11) studies (On-
ine Appendix), including 1,188 women and 999 men.
iabetes cases were defined as self-reported diabetes con-
rmed by a validated supplementary questionnaire. The
ational Diabetes Data Group criteria were used to define
iabetes, because all study subjects were diagnosed with
iabetes before the release of the American Diabetes Asso-
iation criteria in 1997 (12). The validity of this method has
een confirmed (13,14). These patients met the following
election criteria: 1) they were incident cases of type 2
iabetes diagnosed between the cohort baseline (1976 for
HS, and 1986 for HPFS) and the first collection of blood
ample (1990 for NHS, and 1994 for HPFS); 2) they had
lood samples available; and 3) they were free of other
hronic diseases such as cardiovascular disease and cancer at
lood collection (15–17). The study was approved by the
uman Research Committee at the Brigham and Women’s
ospital, Boston, and all participants provided written
nformed consent.
For the purpose of the present study, CHD was defined
s the occurrence of a fatal or nonfatal myocardial infarction
r coronary artery bypass grafting during follow-up through
006. Nonfatal myocardial infarction was confirmed by
eviewing medical records with the criteria of the World
ealth Organization of symptoms plus either typical elec-
rocardiographic changes or elevated levels of cardiac en-
ymes. Physicians who reviewed the records had no knowl-
dge of the self-reported risk factors. Cardiovascular deaths
Abbreviations
and Acronyms
AUC  area under the
receiver-operator
characteristic curve
CHD  coronary heart
disease
CI  confidence interval
GRS  genetic risk score
GWAS  genome-wide
association studies
HbA1c  hemoglobin A1c
HDL  high-density
lipoprotein
HWE  Hardy-Weinberg
equilibrium
NRI  net reclassification
improvement
OR  odds ratio
SNP  single-nucleotide
polymorphismere confirmed by review of medical records or autopsy Ieports with the permission of the next of kin. Sudden
eaths were included in the fatal CHD category. We
xcluded those subjects who were diagnosed with CHD
efore the diagnosis of diabetes, who were diagnosed with
troke and/or angina, who were non-Caucasian minorities,
nd who were missing all genotypes. After these exclusions,
35 women and 203 men were removed, leaving 853
omen (309 CHD case subjects and 544 control subjects)
nd 796 men (345 CHD case subjects and 451 control
ubjects) who were analyzed in this study.
JOSLIN HEART STUDY. The JHS study (Joslin Heart Study)
consists of a series of non-Hispanic White CHD cases and
control subjects, all with type 2 diabetes, who lived in the
greater Boston and attended the Joslin Clinic and/or the
Beth Israel Deaconess Medical Center at the time of their
recruitment. The study protocol and informed consent
procedures were approved by the Joslin Committee on
Human Studies and the Beth Israel Deaconess Medical
Center Committee on Clinical Investigations. All subjects
gave written informed consent. The recruitment and clinical
characteristics of the subjects recruited up to 2006 were
previously described (18). Type 2 diabetes was defined as
diabetes that was diagnosed at age 30 years or older
according to American Diabetes Association criteria (19)
and did not require insulin treatment for at least 2 years after
its diagnosis. The CHD case participants (n  422) were a
andom sample of patients with type 2 diabetes who had a
tenosis 50% in a major coronary artery or a main branch
hereof that was documented by cardiac catheterization at
he Beth Israel Deaconess Medical Center between 2001
nd 2008. All eligible participants were enrolled in the study
t the time of catheterization and examined within 1 month
fter the procedure. Sixty percent of the case patients
eceived diabetes management care at the Joslin Clinic.
ontrol subjects (n  435) were randomly selected from
mong Joslin patients who were identified between 2001
nd 2008 as fulfilling the following criteria: 1) current age
etween 55 and 74 years; 2) type 2 diabetes for 5 years or
ore; 3) negative cardiovascular history (i.e., normal resting
lectrocardiogram, absence of cardiac symptoms, and no
ospital stay for cardiovascular events); and 4) normal
esponse to an exercise treadmill test performed for screen-
ng purposes. All control participants were recruited within
months after the exercise treadmill test. History of
yocardial infarction, smoking, hypertension, and hyper-
holesterolemia and treatment with glucose-lowering drugs
ere determined by a questionnaire administered at the
ime of examination.
easurement of hemoglobin A1c and high-density
ipoprotein. Hemoglobin A1c (HbA1c) and high-density
lipoprotein (HDL) were measured in 1990 to 1991 in the
NHS study, in 1993 to 1999 in the HPFS study and at
examination in the JHS study. The HbA1c was measured by
mmunoassay (Hitachi 911 Analyzer, Roche Diagnostics,
ndianapolis, Indiana) in the NHS and HPFS studies and
S
b
c
C
t
s
(
a
s
p
p
A
s
i
J
G
a
(
q
i

S
f
N
w
(
C
S
s
t
a
e
s
S
a
a
(
l
w
e
f
s
r
s
p
h
G
o
m
0
v
f
b
e
w
p
c
w
(
s
s
v
a
c
d
t
t
m
A
w
v
m
a
p
p
r
2677JACC Vol. 58, No. 25, 2011 Qi et al.
December 13/20, 2011:2675–82 Genetic Susceptibility, CHD, and Diabetesby high-performance (pressure) liquid chromatography
(Tosoh Bioscience, South San Francisco, California) in the
JHS study. The coefficients of variation were 3.8% in
the NHS and HPFS studies and 2.1% in the JHS study.
The HDL was measured on a Hitachi 911 analyzer (Roche
Diagnostics) in the NHS and HPFS studies and on an
Ortho Vitros 5.1 Chemistry Analyzer (Ortho-Clinical Di-
agnostics, Rochester, New York) in the JHS study. The
coefficients of variation were 3.0% with both methods.
ingle-nucleotide polymorphism genotyping. Deoxyri-
onucleic acid was extracted from the buffy coat fraction of
entrifuged blood with the QIAmp Blood Kit (Qiagen,
hatsworth, California) in the NHS and HPFS studies and
he chloroform/phenol method in the JHS study. All
ubjects were typed for 15 single-nucleotide polymorphisms
SNPs) tagging 12 loci that were previously found to be
ssociated with coronary heart disease at the genome-wide
ignificance level of 5 · 108 in GWAS of the general
opulation (Online Table 1). In the NHS and HPFS
articipants, the genotyping was carried out with the Open-
rray SNP Genotyping System (BioTrove, Woburn, Mas-
achusetts). Replicate quality control samples (10%) were
ncluded and genotyped with 99% concordance. In the
HS study, genotyping was carried out by the Joslin DERC
enetics Core by means of TaqMan assays implemented on
n ABI PRISM 7700 HT Sequence Detection System
Applied Biosystems, Foster City, California). Genotyping
uality was tested by including 6 blinded duplicate samples
n each 96-well assay. The average agreement rate was
99%. The call rate was 95% in all 3 studies.
tatistical analysis. The SAS statistical package was used
or all analyses (version 8.2 for UNIX, SAS Institute, Cary,
orth Carolina). Chi-square tests were used to assess
hether genotypes were in Hardy-Weinberg equilibrium
HWE) and to compare genotype frequencies between
HD cases and control subjects. All p values are 2-sided.
INDIVIDUAL LOCUS ANALYSES. Crude odds ratios (ORs) of
CHD and their 95% confidence intervals (CIs) were esti-
mated for each SNP and in each study by means of logistic
regression models in which CHD was considered as the
dependent variable and the SNP genotypes as the indepen-
dent variables according to an additive model. Associations
were then summarized across the 3 studies by meta-analyses
with STATA (version 7.0, StataCorp, College Station,
Texas). The presence of heterogeneity among the 3 studies
was tested by means of chi-square statistics. Because this
test was not significant for any of the SNPs, we calculated
summary ORs according to a fixed-effect model (i.e., by
averaging the natural logarithms of the ORs from individual
studies), weighted by the inverses of their variances (20).
The 3 studies combined had 90% power (alpha  0.05) to
detect ORs in the 1.13-to-1.18 range at the disease allele
frequencies considered in this study. Haplotype analysis was
conducted with the THESIAS program, which is based on ethe Stochastic-EM algorithm (21). We selected the haplo-
types on the basis of a frequency 1% in control subjects.
CALCULATION OF A GRS. A GRS was calculated from 5
NPs that were significantly associated with CHD in the 3
tudies combined. For the GRS calculation, we assumed
hat each SNP was independently associated with risk
ccording to an additive genetic model, which performs well
ven when the true genetic model is unknown or wrongly
pecified (22). In the main analysis, we assumed that each
NP in the panel contributed equally to the risk of CHD
nd calculated the GRS by summing the number of risk
lleles at each polymorphic locus. This score ranged from 0
no risk allele at any of the 5 loci) to 10 (2 risk alleles at each
ocus). However, in sensitivity analyses, we also calculated a
eighted GRS by multiplying the number of risk alleles at
ach locus (0, 1, or 2) for the corresponding beta coefficient
rom the meta-analysis and then summing the products.
EVALUATION OF GRS PERFORMANCE. We analyzed the as-
ociations between GRS and CHD by means of logistic
egression. Predictor coefficients were estimated by regres-
ion models including: 1) only the GRS; 2) only clinical
redictors (age, sex, HbA1c, HDL, and history of smoking,
ypertension, and hypercholesterolemia); and 3) both the
RS and clinical predictors. The area under the receiver-
perator characteristic curve (AUC) was used as an overall
easure of prediction accuracy with a sensitivity cutoff of
.90. Because it is difficult to empirically estimate the
ariance of the accuracy measure estimates, standard errors
or model coefficients and accuracy measures were estimated
y a perturbation-resampling method (23). Because appar-
nt accuracy measure estimates can be overly optimistic
hen the same set of data is used to estimate both the model
arameters and the accuracy of the resulting risk score, we
onsidered a general 3-fold cross-validation procedure in
hich the data were randomly split into a training set
2/3*n) and a validation set (1/3*n). For each of 200 random
plits, we estimated the model parameters with the training
et and calculated the accuracy measure on the basis of the
alidation set. The resulting cross-validated AUC was an
verage overall random splits. Confidence intervals were
entered around the cross-validation estimate with width
etermined by the perturbed variance estimate. To evaluate
he incremental value provided by the GRS, we compared
he predictive accuracy of the model with GRS with the
odel without GRS, both including all clinical predictors.
CI for the difference in AUC when the GSR was added
as constructed with the estimated difference in AUC with
ariance on the basis of the perturbation-resampling
ethod, which accounts for the correlation between the 2
ccuracy measure estimates.
To quantify the improvement in the proportion of ex-
lained variation due to the addition of GRS to the clinical
redictors (24), we used the sum of squares for logistic
egression as a basis for calculating the proportion of
xplained variation.
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Genetic Susceptibility, CHD, and Diabetes December 13/20, 2011:2675–82RECLASSIFICATION ANALYSIS. In addition, we used the
ategory-less net reclassification improvement (NRI) to
uantify the degree of correct reclassification when using the
odel with GRS compared with the model without GRS
25). The NRI quantifies the amount of correct change in
odel-based probabilities introduced by using a model with
new marker. We present the cross-validated estimates,
imilar to AUC. A CI for NRI was constructed with the
ootstrap method.
FAMILY HISTORY VERSUS GENETIC MARKERS. The associa-
tion between GRS and family history of CHD (defined as
the report of at least 1 affected parent) was evaluated by
logistic regression analysis. The effect of CHD family
history on the performance of the GRS as a predictor of
CHD was evaluated by repeating the analyses described in
the previous paragraph with family history added to the
clinical prediction model.
Results
Clinical characteristics of cases and control subjects.
Clinical characteristics of participants at baseline (NHS and
HPFS) or examination (JHS) are summarized in Table 1
according to study and CHD status. Within each study, age
at examination and body weight were similar in subjects
with and without CHD. In the HPFS study, CHD cases
were younger than control subjects at diabetes diagnosis,
whereas no significant case-control differences in this vari-
able were observed in the NHS and JHS studies. In the JHS
study, the proportion of men was significantly higher in
CHD cases than in CHD control subjects. In all 3 popu-
lations, CHD cases had higher HbA1c (a measure of poor
glycemic control), lower HDL values, and a more frequent
history of hypertension and hypercholesterolemia than sub-
jects without evidence of CHD. A history of smoking was
almost twice as common in cases as in control subjects in the
Characteristics of the ParticipantsTable 1 Characteristics of the Participants
NHS
CHD Absent
(n  544)
CHD Present
(n  309) p Value
Men 0 0 —
Age at baseline/examination, yrs 60 6 60 6 0.9
Age at diabetes diagnosis, yrs 52 11 52 9 0.3
Duration of diabetes, yrs 6 8 8 8 0.001
BMI, kg/m2 29.8 6.2 30.0 6.4 0.88
HbA1c 6.7 1.7 7.2 1.8 0.001
History of hypertension 35.5 49.5 0.001
History of hypercholesterolemia 25.5 35.0 0.002
HDL, mg/dl 52 15 49 14 0.002
Smoking
Never 47.7 39.9 0.09
Past 40.3 45.8
Current 12.0 14.3Values are n, %, or mean SD. Characteristics at baseline for the NHS (Nurses’ Health Study) and HPFS (Health P
BMI  body mass index; CHD  coronary heart disease; HbA1c  hemoglobin A1c; HDL  high-densiJHS study; a more modest, nonsignificant association be-
tween smoking and CHD was observed in the NSH and
HPFS studies.
Association between individual loci and CHD. All SNPs
were common in the study samples, with risk allele fre-
quency comparable to the Hapmap reference (CEU) (On-
line Table 2). All SNPs but 1 (rs6725887) were in HWE.
The SNP rs6725887 showed a significant HWE deviation
(p  0.05) in both the NHS and HPFS cohorts (in
non-CHD control subjects as well as in cases and control
subjects combined), possibly due to diabetic patients not
being representative of the general population or to geno-
typing errors. Therefore, we excluded this SNP from further
analysis.
No significant evidence of heterogeneity was observed
among the 3 studies in the effect of the SNPs on CHD risk (all
p values for heterogeneity 0.05), and no significant differ-
ences were observed in the association between SNPs and
CHD between sexes. Five SNPs (rs4977574 [CDKN2A/2B],
rs12526453 [PHACTR1], rs646776 [CELSR2-PSRC1-
SORT1], rs2259816 [HNF1A], and rs11206510 [PCSK9])
showed an association with CHD that went in the same
direction across studies and was in agreement with the associ-
ation pattern described in the previous GWAS reports (Table
2). When the 3 studies were analyzed together, the summary
ORs (95% CI) of CHD for the 5 SNPs were 1.21 (1.08 to
1.35), 1.25 (1.10 to 1.41), 1.17 (1.02 to 1.34), 1.17 (1.04 to
1.32), and 1.26 (1.09 to 1.47), respectively, with no signif-
icant evidence of heterogeneity among studies (Table 2).
The ORs did not change after adjustment for age, sex,
glycemic control, HDL, and history of smoking, hyperten-
sion, and hypercholesterolemia, indicating that the effect of
these SNPs was not mediated by an effect on other cardio-
vascular risk factors. Two other SNPs (rs9818870 at MRAS
and rs998260 at MRPS6-SCL5A3-KCNE2) approached
HPFS JHS
bsent
451)
CHD Present
(n  345) p Value
CHD Absent
(n  435)
CHD Present
(n  422) p Value
0 100 — 57 72 0.001
 11 65 13 0.005 64 6 65 7 0.23
 8 63 8 0.01 52 8 52 10 0.61
 3 3 2 0.22 12 7 13 9 0.66
 4.6 27.5 4.3 0.30 32.3 6 32.1 6 0.82
 1.5 7.5 1.6 0.008 7.3 1.2 7.5 1.4 0.066
3.5 47.5 0.001 70.3 81.5 0.001
7.7 52.5 0.001 80.9 86.5 0.03
 11 39 11 0.001 46 19 39 12 0.001
9.7 35.5 0.49 62.2 34.0 0.001
4.6 58.5 33.6 60.1
5.7 6.0 4.2 5.9CHD A
(n 
10
62
61
4
27.9
7.2
3
2
41
3
5rofessional Follow-up Study) studies and at examination for the JHS study (Joslin Heart Study).
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association with CHD went in the opposite direction of that
observed in the GWAS, the risk allele being associated with
protection (Table 2).
No significant association with coronary artery disease
was observed for the 2 haplotypes defined by SNPs rs2048327,
rs3127599, rs7767084, and rs10755578 in the SLC22A3-
LPAL2-LPA gene cluster on chromosome 6q26–q27 that
ere reported to be associated with increased risk of CHD
n the general population by Tregouet et al. (9) (Online
Table 3). Relative to the most frequent haplotype (TCTC),
the ORs of CHD for the predisposing haplotype CCTC
were 1.02 (95% CI: 0.40 to 2.56), 0.93 (95% CI: 0.34 to
2.56), 0.98 (95% CI: 0.41 to 2.32), and 0.98 (95% CI: 0.57
to 1.67) in the NHS, HPFS, and JHS studies and combined
analysis, respectively. The ORs were larger for the other
predisposing haplotype CTTG but were not significantly
different from 1 with this sample size (1.21 [95% CI: 0.91
to 1.62], 0.97 [95% CI: 0.69 to 1.37], 1.13 [95% CI: 0.85 to
1.50], and 1.11 [95% CI: 0.94 to 1.33]).
Joint genetic effects. No significant interactions were
found between the 5 SNPs associated with CHD risk.
Online Figure 1 shows the distribution of a GRS combining
the risk alleles of the 5 SNPs among the subjects from the
3 studies for whom genotypes were available for all 5 loci
(n  770 for the NHS study, n  696 for the HPFS study,
 800 for the JHS study). The mean GRS was 6.0, 6.0,
nd 6.1 among the control subjects of the NHS, HPFS, and
HS studies, respectively. Increasing GRS values were
ignificantly associated with an increasing risk of CHD in
Associations of Reported CHD SNPs With CHD Risk in NHS, HPFS,Table 2 Associations of Reported CHD SNPs With CHD Risk in
SNPs Genes (chr)
Risk
Allele NHS
rs4977574 CDKN2A/CDKN2B (9p21) G 1.13 (0.93–1.3
rs17465637 MIA3 (1q41) C 1.03 (0.83–1.2
rs9818870 MRAS (3q22) T 0.85 (0.65–1.1
rs12526453 PHACTR1 (6p24) C 1.12 (0.91–1.3
rs9982601 MRPS6-SCL5A3-KCNE2 (21q22) T 0.93 (0.73–1.1
rs646776 CELSR2-PSRC1-SORT1 (1p21) T 1.10 (0.86–1.4
rs2259816 HNF1A (12q24) T 1.06 (0.86–1.3
rs1746048 CXCL12 (10q11) C 1.08 (0.81–1.4
rs1122608 LDLR (19p13) G 1.12 (0.88–1.4
rs11206510 PCSK9 (1p32) T 1.05 (0.80–1.3
chr  chromosome; CI  confidence interval; SNP  single-nucleotide polymorphism; other abbr
Joint Effect of the Loci Significantly AssociatedTable 3 Joint Effect of the Loci Significantly
Genetic Risk
Score
Odds Rati
NHS HPFS
0–5 1.00 1.00
6–7 1.15 (0.79–1.67) 1.18 (0.81–1.71)
8 1.53 (1.10–2.15) 1.87 (1.34–2.60)
Continuous 1.10 (1.00–1.20) 1.22 (1.11–1.34)Abbreviations as in Tables 1 and 2.ll 3 studies, with ORs/allele equal to 1.10 (95% CI: 1.00 to
.20), 1.22 (95% CI: 1.11 to 1.34), and 1.27 (95% CI: 1.16
o 1.40), respectively (Table 3). The GRS explained 2.48%,
.03%, and 3.64% of the variability in addition to traditional
isk factors in HPFS, NHS, and JHS studies, respectively.
n the combined analysis, each risk allele of GRS was
ssociated with a 19% (95% CI: 13% to 26%) increase in the
dds of CHD. As compared with subjects with GRS 5
corresponding to 30% of study subjects), those with GRS
f 6 to 7 (51% of study subjects) and 8 (19% of the study
ubjects) had 25% (95% CI: 0% to 55%) and 94% (95% CI:
0% to 135%) increase in the odds of CHD, respectively.
esults were similar if the GSR was calculated after weigh-
ng each risk allele for the corresponding beta coefficient
rom the combined analysis of the 3 studies, to account for
he differences in effect magnitude among the 5 loci.
erformance of the GRS as a predictor of CHD. Figure 1
hows the receiver-operating characteristic curves of regres-
ion models on the basis of the GRS alone, clinical
redictors alone (including age, sex, HbA1c, HDL, and
istory of smoking, hypertension, and hypercholesterol-
mia), and clinical predictors plus the GRS. The AUC of
he model including the GRS alone ranged from 0.534 in
he NHS study to 0.601 in the JHS study; the AUC of the
linical model ranged from 0.67 in the HPFS study to 0.73
n the JHS study. Addition of the GRS to the clinical model
roduced a significant increase in the AUC in the HPFS
0.025; 95% CI: 0.002 to 0.049) and JHS studies (0.02; 95%
I: 0.004 to 0.035), whereas no significant effect was
bserved in the NHS study (0.006; 95% CI: 0.011 to
JHS, HPFS, and JHS
Odds Ratios, 95% CI
p Value
CombinedHPFS JHS Combined
1.07 (0.88–1.30) 1.51 (1.22–1.87) 1.21 (1.08–1.35) 0.0007
1.15 (0.91–1.45) 0.96 (0.78–1.19) 1.04 (0.91–1.18) 0.57
0.97 (0.73–1.29) 0.85 (0.66–1.11) 0.89 (0.76–1.04) 0.13
1.23 (0.99–1.52) 1.41 (1.14–1.75) 1.25 (1.10–1.41) 0.0002
0.86 (0.66–1.10) 0.87 (0.65–1.18) 0.89 (0.77–1.03) 0.13
1.31 (1.03–1.67) 1.11 (0.88–1.41) 1.17 (1.02–1.34) 0.03
1.25 (1.01–1.55) 1.21 (0.99–1.47) 1.17 (1.04–1.32) 0.0048
0.89 (0.69–1.17) 1.11 (0.85–1.45) 1.02 (0.87–1.19) 0.22
1.07 (0.85–1.35) 0.86 (0.69–1.09) 1.01 (0.88–1.15) 0.92
1.44 (1.10–1.88) 1.33 (1.03–1.72) 1.26 (1.09–1.47) 0.0013
s as in Table 1.
CHDociated With CHD
% CI) Heterogeneity
JHS Combined Q p Value
1.00 1.00 — —
5 (0.98–2.15) 1.25 (1.00–1.55) 0.83 0.66
4 (1.82–3.54) 1.94 (1.60–2.35) 4.50 0.11
7 (1.16–1.40) 1.19 (1.13–1.26) 4.96 0.08andNHS
7)
9)
3)
8)
8)
1)
1)
4)
2)
7)WithAss
os (95
1.4
2.5
1.2
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GRS and CHD observed in this study (Table 3). When the
3 studies were considered together, the apparent AUC was
0.715 (95% CI: 0.693 to 0.736) for the model with both the
GRS and the clinical predictors, as compared with 0.699
(95% CI: 0.677 to 0.720) for the model including only
clinical variables, and 0.577 (95% CI: 0.554 to 0.600) for the
model including only the GRS. The corresponding cross-
validated values were 0.695 (95% CI: 0.674 to 0.717), 0.682
(95% CI: 0.660 to 0.704), and 0.574 (95% CI: 0.550 to
0.597). The cross-validated increase in AUC determined by
the GRS, although relatively small (0.013, 95% CI: 0.008 to
0.018), was significant at the 0.001 level.
Reclassification analysis. Addition of the GRS to the
clinical model produced a significant improvement in net
reclassification as measured by the NRI in the HPFS
(0.2857; 95% CI: 0.123 to 0.448) and JHS studies (0.3661;
Figure 1 Receiver-Operating Characteristic Curves for Coronary
The area under the receiver-operator characteristic curves (AUCs) are based on
body mass index, smoking, glycemic control, history of hypertension, history of ch
score. NHS  Nurses’ Health Study; HPFS  Health Professional Follow-Up Study95% CI: 0.235 to 0.497), whereas no significant improve- fment was observed in the NHS study (0.0200; 95% CI:
0.197 to 0.237). The cross-validated NRI across the 3
studies was significant (0.2776, 95% CI: 0.185 to 0.370).
Genetic markers versus family history. We finally as-
sessed whether the genetic markers could account for part of
the variance of CHD family history and explain its predis-
posing effect on CHD. We limited this analysis to the
HPFS and NHS studies, for which complete data on the
occurrence of CHD in parents were available. A family
history of CHD—defined as the report of at least 1 affected
parent—was significantly associated with an increased risk
of CHD in both the NHS (OR: 1.38, 95% CI: 1.00 to 1.91)
and HPFS studies (OR: 1.56, 95% CI: 1.04 to 2.32). After
adjusting for other risk factors and case-control status, we
did not observe any association between family history and
the genetic score in either cohort (p  0.68 and p  0.99,
espectively). In both studies, the change in AUC resulting
rt Disease in Patients With Type 2 Diabetes
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December 13/20, 2011:2675–82 Genetic Susceptibility, CHD, and Diabetesincluded family history of CHD was similar to that ob-
served when the genetic markers were added to a model
without family history (OR: 0.0188 [95% CI: 0.001 to
0.039] vs. OR: 0.025 [95% CI: 0.002 to 0.049] in the HPFS
study and OR: 0.005 [95% CI: 0.01 to 0.00] vs. OR:
0.006 [95% CI: 0.011 to 0.000] in the NHS study).
Discussion
In this study of 3 CHD case-control series, we found that 5
of 12 loci previously identified as predictors of CHD in
GWAS of the general population also affected CHD risk in
the presence of type 2 diabetes. We also showed that the
genetic determinants of cardiovascular risk in diabetic pa-
tients might be different from the general population.
At all the 5 loci associated with CHD, the association
went in the same direction in the 3 series of diabetic subjects
and was consistent with that previously reported in the
general population (5–9). Some variability was observed in
the strength of the associations among the 3 samples,
although no significant evidence of heterogeneity was de-
tected at any of the 5 loci, indicating that such differences
were compatible with chance. At 2 of the CHD loci
(rs4977574 and rs646776), the effect estimates obtained by a
meta-analysis of our 3 studies were similar to those previously
reported in the general population (8), whereas at the other 3
loci (rs12526453, rs2259816, and rs11206510) effects seemed
to be stronger (Table 2, Online Table 1) (7,8).
Our data indicate that these genetic markers, when
considered jointly, might exert sizable influence on CHD
risk, even though the individual genetic effects seem to be
moderate. Individuals with more than 8 risk alleles had
almost a 2-fold increase in CHD risk as compared with
individuals with 5 risk alleles. Screening the genetic
susceptibility might provide important information to dis-
criminate diabetic individuals at high-risk for cardiovascular
complications from those at lower risk, considering the
relatively high proportion of the 2 extreme groups (19% vs.
30%) in the diabetic population. An added value of the
genetic markers is that they can offer information on CHD
risk early in life when other cardiovascular risk factors such
as hypertension, hypercholesterolemia, or poor glycemic
control have yet to emerge. Such a feature is especially
attractive if we consider that type 2 diabetes is being
diagnosed at an increasingly young age (26).
The genetic markers significantly improved CHD risk
prediction when added to conventional risk factors such as
age, body mass index, sex, smoking, degree of glycemic
control, HDL, and history of hypertension and hypercho-
lesterolemia. This effect, however, was modest. These re-
sults are in line with the previous observations that currently
identified genetic variants might contribute modestly to the
prediction of common disorders such as type 2 diabetes and
cancer (27,28). However, our data suggest that adding the
genetic information to the model might lead to a 28% net kgain with respect to moving the risk estimates toward the
correct direction.
Our data suggest that the architecture of genetic suscep-
tibility to CHD might be different in diabetic patients from
that in the general population. Across all 3 studies, 2 loci,
MRAS and MRPS6-SCL5A3-KCNE2, consistently showed
ssociations with CHD risk that went in the opposite
irection from that in the general population, although such
ffects did not reach statistical significance in the combined
nalyses. Some other loci, such as the haplotype system at
he SLC22A3-LPAL2-LPA locus (9) identified in the gen-
ral population, were not associated with CHD risk in
iabetes. However, the frequencies of the previously re-
orted predisposing haplotypes at the SLC22A3-LPAL2-
PA locus were low in the study samples, approximately
.02 for CCTC and 0.13 to 0.14 for CTTG, and the failure
o replicate the associations might have been partly due to
he inadequate power. The mechanisms underlying the
ifferent genetic effects in diabetic and nondiabetic popula-
ions are not clear. Our previous findings suggest hypergly-
emia or other metabolic abnormalities of the diabetic
ilieu might modulate the genetic effects on cardiovascular
isk in diabetes (18). However, we cannot exclude the
ossibility that the observed differences between the diabetic
atients in our study and those in the general population
ight be due to chance or to differences in study designs.
uture adequately powered studies including both diabetic and
ondiabetic subjects are warranted to verify our findings.
The differences in genetic effects between diabetic sub-
ects and the general population raise the hypothesis that
enetic predictors of CHD might exist that are specific to
iabetes. Identification of these genes will require GWAS
hat are specifically targeted to the diabetic population. The
xistence of other as yet unidentified genetic predictors of
HD is supported by the fact that the currently identified
enetic markers did not explain the predisposing effect of
amily history on CHD observed in our study. A similar
attern has been observed for other common disorders, such
s type 2 diabetes itself (27), prompting an assessment in the
ublished data of the reasons that might account for such
missing heritability” (29). Part of the familial clustering of
HD might be due to the sharing of environmental risk
actors among family members, in addition to the existence
f as yet unidentified genetic factors. Such putative shared
nvironment, however—if it plays a role—should act
hrough mechanisms other than those of known risk factors,
uch as smoking, body mass index, or dyslipidemia, because
he predictive effect of family history was unaffected by
djustment for these variables.
tudy strengths and limitations. Our study has several
ain strengths, namely the replication design with 3 inde-
endent cohorts of diabetic patients, a rigorous definition of
HD, and a sample size that was adequate for the detection
f additive genetic effects of the magnitude reported in the
ublished data. Some limitations, however, should be ac-
nowledged. One limitation concerns the generalizability of
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Genetic Susceptibility, CHD, and Diabetes December 13/20, 2011:2675–82our findings. The NHS and HPFS cohorts consist of health
professionals, and the JHS study consists of patients receiv-
ing their care in an academic environment. Whether our
findings can be extended to the general population of
diabetic subjects remains to be determined. However, our
previous genetic analyses in these cohorts are highly consis-
tent with the observations in other populations (15,30,31).
Our study was also restricted to non-Hispanic Whites to
avoid the possible confounding effect of race. Other genetic
markers might be more effective, on the basis of the known
differences in linkage disequilibrium patterns among races,
in capturing the predisposing effect of the loci described in
this article in other racial groups. Different loci might also
be involved in the modulation of CHD risk in other races.
Conclusions
Five loci recently found to be associated with CHD in
GWAS of the general population were also associated with
CHD among diabetic subjects. Our findings demonstrate
similarities in the genetic susceptibility to CHD between
the diabetic and nondiabetic populations but also highlight
possible peculiarities in the genetic architecture of suscep-
tibility to CHD in diabetes.
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